VANCOUVER, BC, May 23, 2024
/CNW/ -
TSX VENTURE COMPANIES
BULLETIN V2024-1547
CHICANE CAPITAL II CORP.
("CHII.P")
BULLETIN TYPE: New
Listing-CPC-Shares
BULLETIN DATE: May 23, 2024
TSX Venture Tier 2
Company
The Capital Pool Company's (the 'Company')
Prospectus dated April 5, 2024, has
been filed with and accepted by TSX Venture Exchange and the
Ontario, Alberta, British
Columbia, Prince Edward Island Securities Commissions
effective April 09, 2024, under the
provisions of the respective Securities Acts. The common shares of
the Company will be listed and admitted to trading on TSX Venture
Exchange, on the effective dates stated below.
The gross proceeds to be received by the Company
for the public offering (the "Offering") are $219,400 (2,194,000 common shares at $0.10 per share).
Listing Date:
|
At the close of
business (5:01 p.m. EDT) on May 24, 2024.
|
|
|
Commence Date:
|
The common shares
will commence trading on TSX Venture Exchange at the opening
Monday, May 27, 2024, upon confirmation of closing.
|
The closing of the Offering is scheduled to
occur before the market opening on May 27,
2024. A further notice will be issued upon receipt of
closing confirmation.
Corporate
Jurisdiction:
|
Ontario
|
|
|
Capitalization:
|
Unlimited common shares
with no par value of which 4,994,000 common shares are issued and
outstanding
|
Escrowed Shares:
|
2,800,000 common
shares
|
|
|
Transfer Agent:
|
Marrelli Trust Company
Limited
|
Trading Symbol:
|
CHII.P
|
CUSIP Number:
|
16827P101
|
Agent:
|
Haywood Securities
Inc.
|
|
|
Agent's Options:
|
219,400 options to
purchase one share at $0.10 for a period expiring on the earlier of
(i) 60 months following the closing of the Offering; and (ii) 36
months from the date on which the common shares commence trading on
the Exchange, following Completion of the Qualifying
Transaction.
|
For further information, please refer to
the Company's prospectus dated April 5,
2024.
Company Contact:
|
John
Travaglini
|
Company Address:
|
100 King Street West,
Suite 3400
|
|
Toronto, Ontario M5X
1A4
|
Company Phone
Number:
|
(416)
569-7921
|
Company email:
|
john@4frontcapitalpartners.com
|
_______________________________________
BULLETIN V2024-1548
PUREBREAD BRANDS INC.
("BRED")
[formerly COHO COLLECTIVE KITCHENS INC.
("COHO")]
BULLETIN TYPE: Correction, Name Change,
Symbol Change
BULLETIN DATE: May 23, 2024
TSX Venture Tier 2
Company
The following corrects the bulletin dated
May 22, 2024. The correction relates
to the issuer's new name and should have read as follows:
PUREBREAD BRANDS INC. ("BRED")
Effective at the opening Friday, May 24, 2024, the common shares of
Purebread Brands Inc. will commence trading on TSX Venture
Exchange, and the common shares of Coho Collective Kitchens Inc.
will be delisted.
All other information remains
unchanged.
_______________________________________
BULLETIN V2024-1549
LSL PHARMA GROUP INC. ("LSL")
("LSL.DB")
BULLETIN TYPE: New Listing-Debentures,
Correction
BULLETIN DATE: May 23, 2024
TSX Venture Tier 2
Company
Further to the TSX Venture Exchange Bulletin
dated May 22, 2024, the Bulletin
should have read as follows:
Effective at the opening on Friday, May 24, 2024, the debentures of the
Company will commence trading on TSX Venture Exchange (the
"Exchange"). The Company is classified as a "Pharmaceutical
and medicine manufacturing" company (NAICS: 32541).
Corporate
Jurisdiction:
|
Canada
|
|
|
Capitalization:
|
$3,288,000 Debentures
are issued and outstanding
|
|
|
Transfer Agent:
|
TSX Trust
Company
|
Trading Symbol:
|
LSL.DB
|
CUSIP Number:
|
50190NAA2
|
Details of the Debentures: (Note: all
capitalized terms used below and not otherwise defined shall have
the meanings given to them in the Debenture Indenture)
Maturity Date:
|
October 31, 2028 (the
"Maturity Date")
|
|
|
Redemption:
|
Subject to regulatory
approval and subject to any provisions of the Debenture Indenture,
the Company at its option, shall have the right to redeem, either
in whole at any time or in part from time to time before the
Maturity Date by payment of money, the debentures at a price per
Debenture equal to: (i) 110% of the principal amount plus accrued
and unpaid interest if redeemed prior to November 1, 2027; (ii)
102% of the principal amount plus accrued and unpaid interest if
redeemed on or after November 1, 2027 , but prior to the Maturity
Date; or (iii) in the event redemption of the Debentures is
required to secure financing for a bona fide acquisition, (A) 105%
of the principal amount plus accrued and unpaid interest if
redeemed prior to November 1, 2024 , (B) 104% of the principal
amount plus accrued and unpaid interest if redeemed on or after
November 1, 2024 but prior to November 1, 2025, and (C) 102% of the
principal amount plus accrued and unpaid interest if redeemed on or
after November 1, 2025 but prior to the Maturity Date
(the "Redemption Price"). If partial redemption of the Debentures
is carried out prior to the Maturity Date, the Redemption Price
shall only apply to that portion of the principal amount of the
Debentures that is being redeemed.
|
|
|
|
If, at any time
following the date that is 24 months from November 1, 2023, for the
preceding 20 consecutive trading days (i) the daily volume weighted
average trading price of the Class A Shares on the Exchange is
greater than 175% of the Conversion Price; and (ii) the average
daily volume of the Class A Shares traded on the Exchange is no
less than the number obtained when dividing the number of shares
issued upon conversion of the total amount of Debentures
outstanding by twenty (20), LSL Pharma Group Inc. (the "Company")
will have the option to convert all of the principal amount
outstanding of the Debentures at the Conversion Price with at least
thirty (30) days' prior written notice.
|
|
|
Interest:
|
The first interest
payment will be on October 31, 2024 in the amount of $113.025 per
$1,000 principal amount of Debentures and will represent accrued
interest payable from and including November 1, 2023 to but
excluding October 31, 2024.
|
|
|
|
Interest
Rate:
|
|
a) October 31,
2024: 11.3025% calculated on an annual basis for the first payment
on October 31, 2024 (the interest rate of 11.3025% here is due to
the semi-annual compounding in the first year).
b) April 30,
2025 until the Maturity Date: 11% is the Base Rate, which is
subject to adjustment based on the Business Objectives (as defined
below) achieved and is paid out semi-annually on April 30 and
October 31 each year starting as of April 30, 2025 until the
Maturity Date.
|
|
|
|
Please note: The
Exchange will issue a subsequent bulletin in advance of any
interest rate change, and for further avoidance of doubt, the
Exchange will issue a subsequent bulletin prior to November 1, 2024
with details regarding the interest rate for the following interest
period.
|
|
|
|
For further details,
please see below:
|
|
|
|
11% per annum (the
"Base Rate") payable in cash semi-annually on the last day of April
and October of each year with the first interest payment to be paid
on October 31, 2024 ("First Interest Payment Date"). Interest will
accrue from November 1, 2023 (the "Initial Closing Date") up to the
First Interest Payment Date at the Base Rate, compounding
semi-annually on the last day of April and October of each year
(the "Interest Period").
|
|
The annual interest
rate will be recalculated twice every year on April 30th and
October 31st of each year, starting April 30, 2025 (each an
"Interest Rate Review Date") until the Maturity Date, and shall be
equal to the Base Rate less 100 basis points (1.0%) for each
Business Objective (as defined below) achieved (the "Amended Base
Rate"). Upon achievement of a Business Objective (as defined
below), the Amended Base Rate will be effective as of the following
interest payment date of the Debentures (after April 30, 2025)
until the next interest payment date thereafter if Business
Objective 3 (as defined below) is achieved or until the Maturity
Date if a Business Objective 1 or 2 (as defined below) is
achieved.
|
|
|
|
Business Objectives
(each a "Business Objective"):
|
|
- Business Objective 1: the obtention by the
Company of FDA approval for its Steri-Med plant (one-time business
objective);
- Business Objective 2: the completion by the
Company of the acquisition of a business which: 1) complements the
Company's existing product offering and/or creates synergies with
the Company's existing business operations and 2) generated a
minimum of CAD$5.0 million in revenue during the last twelve-month
(12) period preceding the acquisition (one-time business
objective); or
- Business Objective 3: the Company generates a
minimum of CAD$30 million of revenue with a 20% EBITDA margin
during the fiscal period preceding the Interest Rate Review Date
(annual business objective). With respect to Business Objective 3,
the Company's financial performance and revenue shall be calculated
based on its audited financial statements and the Company's EBITDA
margin shall be calculated as EBITDA (not adjusted EBITDA), as
calculated in its audited financial statements, divided by its
revenue (the "Business Objective 3", and the "Business Objective 1
or 2" means the Business Objective other than Business Objective
3).
|
|
|
Conversion:
|
Each Debenture will be
convertible in its entirety into common shares of the Company at
$0.70 per share, which are listed on the TSX Venture Exchange under
ticker symbol "LSL", at the option of the holder at any time prior
to the close of business (5:00 p.m. Eastern time) on the earlier
of: (i) the last Business Day immediately preceding the Maturity
Date of the Debenture, and (ii) the Redemption Date fixed for such
Debenture. The Debenture Indenture makes provision for the
adjustment of the Conversion Price in the events therein
specified.
|
|
|
Day Count
Type:
|
365
|
|
|
Interest Start
Date:
|
November 1, 2023
|
|
|
First Coupon
Date:
|
October 31, 2024
|
|
|
Coupon Dates as
of
|
|
2025 until the Maturity
Date:
|
April 30, October 31
|
|
Please note: The Exchange will issue a subsequent
bulletin in advance of any interest rate change, and for further
avoidance of doubt, the Exchange will issue a subsequent bulletin
prior to November 1, 2024 with details regarding the interest rate
for the following interest period.
|
|
|
Clearing and
Settlement:
|
The Debentures will
clear and settle through CDS.
|
|
|
Board Lot:
|
The Debentures will be
quoted in denominations of $100 and will trade in a board lot size
of $1,000 face value (please note, the Debenture Indenture states
that the Debentures were issued in denominations of
$10).
|
For further information, please refer to the
Exchange bulletin dated May 3, 2024,
the Company's news release dated May 22,
2024, and please consult the debenture indenture dated
November 1, 2023 available
on www.sedarplus.ca (the "Debenture Indenture").
GROUPE LSL PHARMA INC. (« LSL ») (« LSL.DB
»)
TYPE DE BULLETIN : Nouvelle inscription –
Débentures, Correction
DATE DU BULLETIN : Le 23 mai
2024
Société du groupe 2 de TSX Croissance
Suite au bulletin émis par la Bourse de
croissance TSX le 22 mai 2024, le bulletin aurait dû se lire de la
manière suivante :
Les débentures de la société seront admises à la
négociation de la cote de la Bourse de croissance TSX (la « Bourse
») à l'ouverture des affaires vendredi le 24 mai 2024. La
société est catégorisée dans le secteur de la « fabrication de
produits pharmaceutiques et de médicaments » (numéro de SCIAN :
32541)
Juridiction de la
société
|
Canada
|
|
|
Capitalisation
|
3 288 000 $ de
débentures sont émis et en circulation
|
|
|
Agent des transferts
:
|
Compagnie TSX
Trust
|
Symbole au
téléscripteur :
|
LSL.DB
|
Numéro de CUSIP :
|
50190NAA2
|
Détails des débentures (Note : tous les termes
utilisés ci-dessous qui ne sont pas autrement définis, ont le sens
qui leur est accordé dans l'acte de débentures)
Date d'échéance :
|
31 octobre 2028 (la
« date d'échéance »)
|
|
|
Remboursement :
|
Sous réserve de
l'approbation réglementaire et de toute disposition de l'acte de
débentures, la société, à son gré, aura le droit de rembourser,
soit en totalité à tout moment, soit en partie de temps à autre
avant la date d'échéance (telle que définie ci-dessous) par
paiement en espèce, les débentures à un prix par débenture égal
à : (i) 110 % du capital plus les intérêts courus et
impayés si remboursés avant le 1 novembre 2027; (ii) 102 % du
montant en capital majoré des intérêts courus et impayés en cas de
remboursement le 1 novembre 2027 ou après, , mais avant la date
d'échéance; ou (iii) dans le cas où le remboursement des débentures
est requis pour garantir le financement d'une acquisition
véritable, (A) 105 % du capital plus les intérêts courus et impayés
en cas de remboursement avant le 1 novembre 2024, (B) 104 % du
montant en principal plus les intérêts courus et impayés en cas de
remboursement à compter du 1 novembre 2024, mais avant le
1 novembre 2025, et (C) 102 % du montant en capital
majoré des intérêts courus et impayés en cas de remboursement à
compter du 1 novembre 2025, mais avant la date d'échéance (le «
prix de remboursement »). Si le remboursement partiel des
débentures est effectué avant la date d'échéance, le prix de
remboursement s'appliquera uniquement à la partie du capital des
débentures qui est remboursée.
|
|
|
|
Si, à tout moment
après la date qui tombe 24 mois après le 1 novembre 2023, pendant
les 20 jours de négociation à la bourse consécutifs précédents, (i)
le cours moyen pondéré en fonction du volume quotidien des actions
de catégorie A à la Bourse est supérieur à 175 % du prix de
conversion, et (ii) le volume quotidien moyen des actions de
catégorie A négociées à la Bourse n'est pas inférieur au nombre
obtenu en divisant par vingt (20) le nombre d'actions émises lors
de la conversion du montant total des débentures en circulation,
Groupe LSL Pharma Inc. (la « société » ) aura
l'option de convertir la totalité du capital des débentures en
circulation au prix de conversion, moyennant un préavis écrit d'au
moins trente (30) jours.
|
|
|
Taux d'intérêt :
|
Le premier paiement
d'intérêts aura lieu le 31 octobre 2024 au montant de 113,025 $ par
tranche de 1 000 $ de capital des débentures et représentera les
intérêts courus payables à partir du 1er novembre 2023
inclusivement jusqu'au 31 octobre 2024
exclusivement.
|
|
|
Taux
d'intérêt :
|
a) Le
31 octobre 2024 : 11,3025% calculé sur une base annuelle pour
le premier paiement daté du 31 octobre 2024 (ce taux d'intérêt de
11,3025 % est dû à l'intérêt composé semestriellement dans la
première année)
b) Le
30 avril 2025 jusqu'à la date d'échéance : 11% est le taux de
base, qui est sujet à ajustement en vertu des objectifs commerciaux
(tels que définis ci-dessous) atteints et est payé semestriellement
le 30 avril et le 31 octobre de chaque année dès le 30 avril 2025
jusqu'à la date d'échéance.
|
|
|
|
Veuillez
noter : La Bourse émettra un bulletin préalablement à un
changement de taux d'intérêt, et pour éviter tout doute, la Bourse
émettra un bulletin subséquent avant le 1 novembre 2024 avec les
détails concernant le taux d'intérêt pour la période d'intérêt
suivante.
|
|
|
|
Pour plus de
détails, veuillez voir ci-dessous :
|
|
|
|
11% par année (le
« taux de base »), payable en espèces semestriellement le
dernier jour d'avril et d'octobre de chaque année, le premier
paiement d'intérêt devant être effectué le 31 octobre 2024 («
première date de paiement d'intérêt »). Les intérêts courront à
partir du 1er novembre 2023 (la « date de clôture initiale »)
jusqu'à la première date de paiement d'intérêt au taux de base,
composés semestriellement le dernier jour d'avril et d'octobre de
chaque année (la « période d'intérêt »).
|
|
Le taux d'intérêt
annuel sera recalculé deux fois par an, le 30 avril et le 31
octobre de chaque année, à partir du 30 avril 2025 (chacune étant
une « date de révision du taux d'intérêt ») jusqu'à la date
d'échéance, et sera égal au taux de base moins 100 points de base
(1,0%) pour chaque objectif commercial (tel que défini ci-dessous)
atteint (le « taux de base modifié »). Lorsqu'un objectif
commercial est atteint, le taux de base modifié sera effectif à
partir de la date de paiement d'intérêts suivante des débentures
(après le 30 avril 2025) jusqu'à la prochaine date de paiement
d'intérêts par la suite si l'objectif commercial 3 (tel que défini
ci-dessous) est atteint ou jusqu'à la date d'échéance si l'objectif
commercial 1 ou 2 (tel que défini ci-dessous) est
atteint.
|
|
|
|
Objectifs commerciaux
(chacun étant un « objectif commercial ») :
|
|
- Objectif commercial 1 : l'obtention par
la société de l'approbation de la FDA pour son usine Steri-Med
(objectif commercial ponctuel);
- Objectif commercial 2 : la réalisation
par la société de l'acquisition d'une entreprise qui : (1) complète
l'offre de produits existante de la société et/ou crée des
synergies avec les opérations commerciales existantesf5bff de
la société ; et (2) a généré un minimum de 5,0 M$ CAD de revenus au
cours des douze (12) derniers mois précédant l'acquisition
(objectif commercial ponctuel); ou
- Objectif commercial 3 : la société
génère un minimum de 30 M$ CAD de revenus avec une marge du BAIIA
de 20 % au cours de l'exercice financier précédant la date de
révision du taux d'intérêt (objectif commercial annuel). En ce qui
concerne l'objectif commercial 3, la performance financière et le
chiffre d'affaires de la société sont calculés sur la base de ses
états financiers audités et la marge EBITDA de la société
correspond à l'EBITDA (et non à l'EBITDA ajusté), tel que calculé
dans ses états financiers audités, divisé par son chiffre
d'affaires (l'« objectif commercial 3 », et
l'« objectif commercial 1 ou 2 » désigne l'objectif commercial
autre que l'objectif commercial 3).
|
Conversion :
|
Chaque débentures sera
convertible dans son entièreté en action ordinaires de la société à
un prix de $0.70 par action, qui sont inscrites sur la Bourse de
croissance TSX sous le symbole « LSL », au gré du
porteur, à tout moment avant la fermeture des bureaux (17h00, heure
de l'Est) à la première des dates suivant : (i) le dernier
jour ouvrable précédant immédiatement la date d'échéance de la
débenture, et (ii) la date de remboursement fixée pour cette
débenture. L'acte de débentures prévoit l'ajustement du prix de
conversion dans les événements qui y sont précisés.
|
|
|
Type de décompte des
jours:
|
365
|
|
|
Date de début des
intérêts:
|
Le 1 novembre
2023
|
|
|
Date du premier
coupon:
|
Le 31 octobre
2024
|
|
|
Dates des coupons
dès
|
|
2025 jusqu'à la
date
|
|
d'échéance :
|
30 avril, 31
octobre
|
|
Veuillez
noter : La Bourse émettra un bulletin préalablement à un
changement de taux d'intérêt, et pour éviter tout doute, la Bourse
émettra un bulletin subséquent avant le 1 novembre 2024 avec les
détails concernant le taux d'intérêt pour la période d'intérêt
suivante.
|
|
|
Compensation et
règlement :
|
Les débentures seront
compensées et réglées auprès de CDS.
|
|
|
Lot régulier :
|
Les débentures seront
cotées en incréments de 100 $ et seront négociées par lots
réguliers d'une valeur nominale de 1 000 $ (veuillez noter que
l'acte de débenture établit que les débentures ont été émises en
incréments de 10 $).
|
Pour plus d'information, veuillez-vous
référez au bulletin émis par la Bourse le 3 mai 2024, au communiqué
de presse émis par la société le 22 mai 2024, et veuillez consulter l'acte de débentures
daté du 1er novembre 2023 disponible sur
www.sedarplus.ca (l'« acte de débentures »).
_______________________________________
NEX COMPANY
BULLETIN V2024-1550
PACIFIC ARC RESOURCES LTD. ("PAV.H")
BULLETIN TYPE: Resume Trading
BULLETIN DATE: May 23, 2024
NEX Company
Further to the Company's press release dated May 7, 2024, effective at the opening on
Monday, May 27, 2024, shares
of the Company will resume trading. The Company's proposed Change
of Business as initially announced on November 24, 2023, has been terminated.
_______________________________________
24/05/23 - TSX Venture
Exchange Bulletins
TSX VENTURE COMPANIES
BULLETIN V2024-1551
APEX RESOURCES INC.
("APX")
BULLETIN TYPE: Property-Asset
or Share Purchase Agreement and Private
Placement-Non-
Brokered
BULLETIN DATE:
May 23, 2024
TSX Venture
Tier 2 Company
Fundamental Acquisition:
TSX Venture Exchange (the "Exchange") has
accepted for filing documentation with respect to the arm's length
acquisition of 100% interest in a private company ("Privco"), which
holds a 100% option (the "Underlying Option Agreement") over the
consolidated minerals rights of the Lithium Creek Property in
Nevada (the "Property") from an
underlying optionor (the "Underlying Optionor"). The Company will
purchase Privco for $80,000 USD cash
and issue 18,000,000 common shares, which are subject to TSXV Tier
2 value escrow requirements, at a deemed price of $0.07 CAD per share of the Company to the vendors
of Privco. The terms of the Underlying Option Agreement provide for
Privco to acquire 100% of the Property by completing the following
to the Underlying Optionor:
Date for
Completion
|
Option Payment
(USD)
|
Exploration &
Development
Expenditures (USD)
|
1st Anniversary of
Effective Date*
|
$100,000
|
$300,000
|
2nd Anniversary of
Effective Date
|
$150,000
|
$500,000
|
3rd Anniversary of
Effective Date
|
$300,000
|
$1,000,000
|
4th Anniversary of
Effective Date
|
$600,000
|
$2,000,000
|
5th Anniversary of
Effective Date
|
$1,200,000
|
$3,000,000
|
6th Anniversary of
Effective Date
|
$Nil
|
$5,000,000
|
TOTAL
|
$2,400,000**
|
$11,800,000
|
|
|
|
*The Effective
Date of the Underlying Option Agreement is August 25,
2023.
|
**Down payment
(non-refundable) in the amount of $50,000 USD was also made to the
Underlying Optionor (paid by Privco) is included in the $2,400,000
USD.
|
Upon closing of the acquisition of Privco, the
Company will assume the obligations under the Underlying Option
Agreement with the Underlying Optionor.
There are certain milestone payments and a 3.0%
GOR payable to the Underlying Optionor, with a 1.5% GOR buyback
provision the Company can exercise. These are outlined in the
Company's press release dated May 23,
2024.
For further details, please refer to the
Company's news releases dated January 9,
2024, February 26, 2024,
May 8, 2024, and May 23, 2024.
Private Placement:
Financing Type:
|
Non-Brokered Private
Placement
|
|
|
Gross Proceeds:
|
$630,000
|
|
|
Offering:
|
9,000,000 Listed Shares
with 9,000,000 warrants attached.
|
|
|
Offering Price:
|
$0.07 per Listed
Share
|
|
|
Warrant Exercise
Terms:
|
$0.12 per warrant for a
2-year period.
|
|
|
Non-Cash
Commissions:
|
N/A
|
|
|
Public
Disclosure:
|
Refer to the company's
news release(s) dated January 9, 2024, and May 23, 2024.
|
_______________________________________
BULLETIN V2024-1552
DLP RESOURCES INC.
("DLP")
BULLETIN TYPE: Private
Placement-Non-Brokered; Private
Placement-Brokered
BULLETIN DATE: May 23, 2024
TSX Venture Tier 2
Company
Financing Type:
|
Brokered and
Non-Brokered Private Placement
|
Gross Proceeds:
|
$6,423,682
|
Offering:
|
16,059,205 Listed
Shares with 16,059,205 warrants attached
|
|
|
Offering Price:
|
$0.40 per Listed
Share
|
|
|
Warrant Exercise
Terms:
|
$0.54 per warrant for a
three-year period
|
|
|
|
|
Non-Cash
Commissions:
|
|
Shares
|
Warrants
|
|
Finders
(Non-Brokered)
|
N/A
|
280,175
|
|
|
|
|
|
Agents
(Brokered):
|
|
|
|
Paradigm Capital
Inc.
|
N/A
|
575,361
|
|
Canaccord Genuity
Corp.
|
N/A
|
143,840
|
|
|
|
|
|
Commission Terms: Each
non-transferable warrant is exercisable at $0.40 for a two-year
period.
|
|
|
|
|
Public
Disclosure:
|
Refer to the company's
news release(s) dated April 10, 2024, and May 03, 2024.
|
_______________________________________
BULLETIN V2024-1553
GENERAL ASSEMBLY HOLDINGS LIMITED
("GA")
BULLETIN TYPE: Property-Asset or Share
Disposition Agreement
BULLETIN DATE: May 23, 2024
TSX Venture Tier
2 Company
TSX Venture Exchange has accepted for filing
documentation pertaining to a share purchase agreement (the
"Agreement") with an arm's length purchaser, pursuant to which the
Company disposed of its interests in 2499754 Ontario Inc., GA CPG
Limited and GA Subscriptions Limited. Under the terms of the
Agreement, the Company received consideration of $1 for the disposition.
The Company's shareholders approved the
disposition at an annual general and special meeting of
shareholders held on May 3, 2024.
For further details, please refer to the
Company's management information circular dated April 5, 2024
and news releases dated March 25,
2024 and May 21, 2024, each of
which is available on SEDAR+.
_______________________________________
BULLETIN V2024-1554
GREAT PACIFIC GOLD CORP.
("GPAC")
BULLETIN TYPE: Property-Asset
or Share Purchase
Agreement
BULLETIN DATE: May 23, 2024
TSX Venture Tier 2
Company
TSX Venture Exchange has accepted for filing an
amalgamation agreement (the "Agreement") dated April 12, 2024. Pursuant to the terms of the
Agreement, the Company acquired Tinga
Valley Copper & Gold Corp. ("Tinga"), which indirectly
owns the Tinga Valley Property, which comprises 347 square km and
is located in Papua New Guinea. By
way of consideration, the Company issued 12,500,000 common shares
to the shareholders of Tinga.
An arms-length advisor received up to 600,000
common shares in consideration for financial advisory services
provided to the Company in connection with its acquisition of
Tinga.
For further details, please refer to the
Company's news release dated April 15,
2024 and May 22, 2024.
_______________________________________
BULLETIN V2024-1555
LANESBOROUGH REAL ESTATE INVESTMENT TRUST
("LRT.UN")
BULLETIN TYPE:
Halt
BULLETIN DATE: May 23,
2024
TSX Venture Tier 2 Company
Effective at 5:42 a.m.
PST, May 23, 2024, trading in
the shares of the Company was halted, pending clarification market
activity; this regulatory halt is imposed by Investment Industry
Regulatory Organization of Canada,
the Market Regulator of the Exchange pursuant to the provisions of
Section 10.9(1) of the Universal Market Integrity Rules.
_______________________________________
BULLETIN V2024-1556
LANESBOROUGH REAL ESTATE INVESTMENT TRUST
("LRT.UN")
BULLETIN TYPE: Resume
Trading
BULLETIN DATE: May
23, 2024
TSX Venture Tier 2 Company
Effective at 7:45 a.m.
PST, May 23, 2024, shares of
the Company resumed trading, an announcement having been made.
_______________________________________
BULLETIN V2024-1557
ORACLE COMMODITY HOLDING CORP.
("ORCL")
BULLETIN TYPE: Private
Placement-Non-Brokered
BULLETIN DATE: May 23, 2024
TSX Venture Tier 2
Company
Financing Type:
|
Non-Brokered Private
Placement
|
|
|
Gross Proceeds:
|
$10,000
|
|
|
Offering:
|
200,000 Listed Shares
with 200,000 warrants attached
|
|
|
Offering Price:
|
$0.05 per Listed
Share
|
|
|
Warrant Exercise
Terms:
|
$0.06 per warrant for a
3-year period
|
|
|
Non-Cash
Commissions:
|
N/A
|
|
|
Public
Disclosure:
|
Refer to the company's
news release dated May 10, 2024.
|
_______________________________________
BULLETIN V2024-1558
PPX MINING CORP. ("PPX")
BULLETIN
TYPE: Private Placement-Non-Brokered; Amendment
BULLETIN DATE: May 23,
2024
TSX Venture Tier 2 Company
AMENDMENT:
Further to the TSX Venture Exchange Bulletin
dated April 25, 2024 the Company
advises that the following information is amended:
Private Placement- Non-Brokered
|
Aggregate # of
Shares
|
Aggregate # of Warrants
|
Finder's Fee
|
1,167,101
|
1,167,101
|
All other details remain unchanged, please refer
to the Company's news release dated May 14,
2024.
_______________________________________
BULLETIN V2024-1559
SEGO RESOURCES INC. ("SGZ")
BULLETIN
TYPE: Private Placement-Non-Brokered
BULLETIN
DATE: May 23,
2024
TSX Venture Tier 2 Company
Financing Type:
|
Non-Brokered Private
Placement
|
|
|
Gross Proceeds:
|
$200,000
|
|
|
Offering:
|
10,000,000 Listed
Shares with 10,000,000 warrants attached
|
|
|
Offering Price:
|
$0.02 per Listed
Share
|
|
|
Warrant Exercise
Terms:
|
$0.05 per warrant for a
2-year period
|
Non-Cash
Commissions:
|
|
Shares
|
Warrants
|
|
Finders
(Aggregate)
|
N/A
|
47,250
|
|
|
|
Commission Terms: Each
non-transferable warrant is exercisable at $0.05 for a 2-year
period.
|
|
|
Public Disclosure:
|
Refer to the company's
news release(s) dated March 14, 2024, March 15, 2024 and May 1,
2024.
|
_______________________________________
BULLETIN V2024-1560
SIMPLY BETTER BRANDS CORP.
("SBBC")
BULLETIN TYPE: Private
Placement-Non-Brokered
BULLETIN DATE: May 23, 2024
TSX Venture Tier 1
Company
Financing Type:
|
Non-Brokered Private
Placement
|
|
|
Gross Proceeds:
|
$4,000,000
|
|
|
Offering:
|
11,428,568 Listed
Shares with 5,714,281 warrants attached
|
|
|
Offering Price:
|
$0.35 per Listed
Share
|
|
|
Warrant Exercise
Terms:
|
$0.45 per warrant for a
2-year period
|
|
|
Non-Cash
Commissions:
|
|
Shares
|
Warrants
|
|
Finders' Fee
(Aggregate)
|
N/A
|
147,000
|
|
|
|
|
|
Commission Terms: Each
non-transferable warrant is exercisable at $0.45 for a 2-year
period.
|
|
|
Public
Disclosure:
|
Refer to the company's
news release(s) dated April 17, 2024, April 29, 2024 and May 9,
2024.
|
_______________________________________
BULLETIN V2024-1561
TACTICAL RESOURCES CORP.
("RARE")
BULLETIN TYPE: Private
Placement-Non-Brokered, Convertible Debenture/s
BULLETIN
DATE: May 23,
2024
TSX Venture Tier 2 Company
Financing Type:
|
Non-Brokered Private
Placement
|
|
|
Offering:
|
$200,000 principal
amount of convertible debenture, convertible into 2,000,000 Listed
Shares with 2,000,000 warrants attached
|
|
|
Conversion Price:
|
$0.10 per Listed
Share
|
|
|
Maturity date:
|
May 17, 2026
|
|
|
Interest rate:
|
10% per
annum
|
|
|
Warrant Exercise
Terms:
|
$0.15 per warrant for a
three year period
|
|
|
Non-Cash
Commissions:
|
|
Shares
|
Warrants
|
|
Finders
(Aggregate)
|
N/A
|
N/A
|
|
|
|
|
Public
Disclosure:
|
Refer to the company's
news releases dated March 21, 2024 and May 17, 2024.
|
_______________________________________
SOURCE TSX Venture Exchange